German Scientists Crack Code on Covid-19 Nasal Vaccine with Promising Results in Hamster Studies.
Researchers at the Max Delbruck Center for Molecular Medicine in Berlin have made breakthroughs in developing a nasal vaccine against Covid-19, which shows early promise by shutting down infections in the nose and throat. In experiments conducted on hamsters, two doses of the live but weakened vaccine successfully blocked the virus from replicating itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness.
The German team's vaccine takes a novel approach to the classic method of weakening a virus so it can be used as a vaccine. By manipulating the genetic material of the Covid-19 virus, they've created a weakened version that closely mimics the process of a natural infection, eliciting a stronger immune response in animals. This is achieved by presenting the entire coronavirus to the body, rather than just its spike proteins.
The results are impressive, with two doses of the vaccine proving more effective than mRNA-based vaccines and those using an adenovirus to ferry instructions into cells. The researchers believe that this approach could be a game-changer in preventing Covid-19 infections by boosting mucosal immunity, which is critical for fighting respiratory infections.
However, experts caution that more tests are needed before the vaccine can be widely used. The team plans to conduct phase I clinical trials and has partnered with a Swiss company called RocketVax to start this process. Dr. Greg Poland, who designs vaccines at the Mayo Clinic, notes that while the results look promising, it's crucial to repeat these findings in primates and humans before deploying them.
The development of nasal vaccines is gaining momentum globally, with several companies working on similar approaches. At least four nasal vaccines are currently in late-stage testing in people, according to the World Health Organization's vaccine tracker.
While there are challenges ahead, including the need for an updated version of the German team's vaccine to combat emerging variants like Omicron, experts see this approach as a promising way forward in combating respiratory infections.
Researchers at the Max Delbruck Center for Molecular Medicine in Berlin have made breakthroughs in developing a nasal vaccine against Covid-19, which shows early promise by shutting down infections in the nose and throat. In experiments conducted on hamsters, two doses of the live but weakened vaccine successfully blocked the virus from replicating itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness.
The German team's vaccine takes a novel approach to the classic method of weakening a virus so it can be used as a vaccine. By manipulating the genetic material of the Covid-19 virus, they've created a weakened version that closely mimics the process of a natural infection, eliciting a stronger immune response in animals. This is achieved by presenting the entire coronavirus to the body, rather than just its spike proteins.
The results are impressive, with two doses of the vaccine proving more effective than mRNA-based vaccines and those using an adenovirus to ferry instructions into cells. The researchers believe that this approach could be a game-changer in preventing Covid-19 infections by boosting mucosal immunity, which is critical for fighting respiratory infections.
However, experts caution that more tests are needed before the vaccine can be widely used. The team plans to conduct phase I clinical trials and has partnered with a Swiss company called RocketVax to start this process. Dr. Greg Poland, who designs vaccines at the Mayo Clinic, notes that while the results look promising, it's crucial to repeat these findings in primates and humans before deploying them.
The development of nasal vaccines is gaining momentum globally, with several companies working on similar approaches. At least four nasal vaccines are currently in late-stage testing in people, according to the World Health Organization's vaccine tracker.
While there are challenges ahead, including the need for an updated version of the German team's vaccine to combat emerging variants like Omicron, experts see this approach as a promising way forward in combating respiratory infections.